DBV Technologies SA

DBV Technologies Update

13 Mar 2023 00:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

07 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

02 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

02 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

21 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

10 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

23 Jan 2023 15:30:00 By Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022

04 Jan 2023 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial  

23 Dec 2022 00:30:00 By Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022

08 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

22 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

09 Nov 2022 00:30:00 By Nasdaq GlobeNewswire

DBV Technologies Reports Third Quarter Financial Results and Business Update

03 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

31 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022

20 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

03 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

21 Sep 2022 16:45:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

07 Sep 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Present at Upcoming Investor Conferences

02 Sep 2022 15:30:00 By Nasdaq GlobeNewswire

DBV Technologies Reports Second Quarter 2022 Financial Results

01 Aug 2022 15:30:00 By Nasdaq GlobeNewswire